Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART) Nolasiban treatment shown to significantly increase Live Birth Rate…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer
Visnova H., Tournaye H. J., Humberstone A., Terrill P., Macgregor L., Loumaye E.
ASRM 2018, 6-10 October 2018, Denver, CO
Fertility and Sterility September 2018 Volume 110, Issue 4, Supplement, Page e45, Abstract O101
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018
Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA – October 5, 2018– ObsEva SA (NASDAQ: OBSV / SIX:…
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety…
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain
Linzagolix overall efficacy and safety maintained or improved at week 24 Linzagolix 75mg once daily showed no clinically significant impact…
Investora 6th Swiss Small and Mid-Cap Conference
Date & Time: 27 Sep 2018 4:15 p.m. CEST / 10:15am EDT Location: Zurich, Switzerland
BioCentury’s 25th Annual NewsMakers in the Biotech Industry Conference
Click here for webcast Date & Time: Friday, September 7, 2018 11:30 a.m. ET Location: New York
Baird 2018 Global Healthcare Conference
Click here for webcast Date & Time: Thursday, September 6, 2018 10:50 a.m. ET Location: New York
Rodman & Renshaw 20th Annual Global Investment Conference
Click here for webcast Date & Time: Wednesday, September 5, 2018 5:05 p.m. ET Location: New York
ObsEva SA to Participate in September Investor Conferences
Geneva, Switzerland and Boston, MA – August 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…